The Centers for Disease Control and Prevention (CDC) has suspended diagnostic testing for more than two dozen infectious diseases, creating a significant gap in the nation’s public health surveillance infrastructure. The agency announced the pause this week, affecting a wide array of pathogens ranging from common viral infections to rare parasitic diseases.
This decision comes as the agency faces severe internal turmoil, with reports indicating that the CDC temporarily halts testing for several infectious diseases primarily due to critical staffing shortages. Although the agency has framed the move as a routine quality review, internal data and external reports suggest a more systemic collapse of specialized laboratory expertise.
For many state and local health departments, the CDC serves as the final line of defense. When local laboratories lack the sophisticated equipment or specialized expertise to identify a rare pathogen, they rely on the federal agency to provide a definitive diagnosis. The current suspension threatens this safety net, potentially delaying the identification of outbreaks and the implementation of life-saving treatments.
The Scope of Diagnostic Suspensions
The list of unavailable tests includes a mix of common pathogens and rare, geographically specific illnesses. Among the suspended services are assays for the Epstein-Barr virus and the varicella zoster virus, the latter of which is responsible for chickenpox and shingles. For these specific infections, the CDC noted that commercial testing alternatives remain available to the public and healthcare providers.
However, the pause is more concerning for less common organisms where commercial options are scarce or nonexistent. This includes testing for the virus responsible for “sloth fever” and parasitic worms associated with “snail fever.” In these instances, the CDC is often the only facility in the United States capable of providing a confirmed diagnosis.
In an official statement, a CDC spokesperson described the situation as a temporary measure, stating: “Several infectious disease tests are temporarily paused as CDC evaluates these assays as part of our routine review to uphold our commitment to high quality laboratory testing.” The spokesperson added that the agency is coordinating with state and local partners to find alternative laboratories when necessary.
A Hollowed-Out Laboratory Workforce
Despite the official narrative of a “routine review,” the suspension follows a period of aggressive workforce reductions. A combination of targeted layoffs, hiring freezes, and a surge in resignations has depleted the agency’s ranks of experienced scientists. According to estimates from the Associated Press, total staffing at the agency has dropped by 20% to 25% over the past year.
The loss of personnel is not evenly distributed across the agency but is concentrated in highly specialized units. The impact on the rabies and poxvirus teams is particularly acute. By July, the rabies team is expected to have only one expert capable of providing clinical guidance to state and local officials. The poxvirus team, meanwhile, is reported to have no remaining experts to lead its operations, according to reporting by the New York Times.
The National Public Health Coalition, a group formed by current and former employees, reports that the malaria division has seen even more severe cuts. These reductions are the result of a tumultuous year that began when the Trump administration notified more than a thousand employees that they were losing their jobs—a move that erased entire offices before being partially reversed days later.
| CDC Unit | Staffing Change | Current Status/Capacity |
|---|---|---|
| Agency-Wide | 20% to 25% Decrease | Significant reduction in total headcount |
| Rabies Unit | ~50% Decrease | One expert remaining by July |
| Poxvirus Unit | ~50% Decrease | Zero experts remaining |
| Malaria Division | Severe Reduction | Critical capacity loss |
Policy Upheaval and Vaccine Recommendations
The laboratory crisis is occurring alongside a broader restructuring of the agency’s advisory functions. In June, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. Removed all members of the Advisory Committee on Immunization Practices (ACIP) and hand-picked new replacements. This move was later stayed by a federal judge who ruled that the action likely violated federal law.
This legal stalemate has left the United States without a functioning advisory committee to update and maintain vaccine schedules. Several critical immunizations are no longer officially recommended. This includes the most recent versions of the flu and Covid-19 shots, as well as the RSV shot for infants.
The lack of recommendation has immediate practical consequences for the Vaccines for Children program, which provides immunizations for more than half of the children in the U.S. Without the ACIP’s guidance, the inclusion of new vaccines in this federal program is stalled, potentially leaving millions of infants and children without access to updated protections.
What Which means for Public Health
The intersection of lost laboratory capacity and a paralyzed advisory committee creates a dual vulnerability. While the CDC maintains that it can assist state partners in finding alternative labs, the reality is that many “alternative” labs do not exist for rare pathogens. When the federal government loses its “gold standard” diagnostic capability, the window for detecting an emerging infectious disease narrows.
For clinicians, this means a higher reliance on clinical suspicion rather than laboratory confirmation for certain rare diseases. For public health officials, it means a diminished ability to track the movement of pathogens across state lines, which is essential for preventing pandemics.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for diagnostic testing and vaccination guidance.
The CDC has indicated that it anticipates some of the suspended tests will return to service in the coming weeks. The next critical checkpoint will be the agency’s updated test directory and the resolution of the federal court’s stay regarding the ACIP appointments, which will determine if the U.S. Can resume formal vaccine recommendations.
We invite you to share this story and join the conversation in the comments below.
